Antibody-drug conjugates (ADCs) represent a revolutionary class of targeted therapeutics in oncology and beyond. As these complex molecules advance through development pipelines, the role of drug metabolism and pharmacokinetics (DMPK) becomes increasingly crucial. Innovative DMPK solutions  are essential for optimizing ADC design, enhancing stability, and predicting clinical performance. This article explores how state-of-the-art DMPK services are shaping the future of ADC development, offering insights into the latest techniques and approaches that are accelerating the path from laboratory to patient.   Table of contents: Tailoring In Vitro DMPK Profiling Services for Next-Generation ADCs Unlocking the Potential of ADCs with Integrated DMPK and Pharmacology Approaches Optimizing Drug-to-Antibody Ratio Through Innovative DMPK Techniques Accelerating Clinical DMPK Drug Development for ADC Candidates   Tailoring In Vitro DMPK Profiling Services for Next-Generation A...